Targets › RAC1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Plasma membrane-associated small GTPase which cycles between active GTP-bound and inactive GDP-bound states. In its active state, binds to a variety of effector proteins to regulate cellular responses such as secretory processes, phagocytosis of apoptotic cells, epithelial cell polarization, neurons adhesion, migration and differentiation, and growth-factor induced formation of membrane ruffles. (UniProt, P63000)
Open in Phaseline: the race on RAC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| MBQ Pharma | MBQ-167 Rho GTPase inhibitor (Rac and Cdc42 inhibitor) | RAC1, CDC42 | Phase 1 | Breast Cancer | Dec 2026 |
Breast Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.